The Role of the CD38 Receptor in the Progression of HIV

CD38, or cyclic ADP ribose hydrolase, is a glycoprotein found on the surface of many immune cells. Binding of CD38 to its target ligand results in T cell co-stimulation, B cell maturation, and induction of cytokine production by several cell types.

HIV infection is characterized by the depletion of CD4+ T cells, leading to a hyperactive immune system. The depletion of CD4+ T cells has long been correlated with the overexpression of the cell surface adhesion receptor protein, CD38.

Skip to:

  1. CD38 as a predictor of CD4+ T cell depletion
  2. Mechanism of action
  3. Products of CD38 catalysis
  4. CD38 as a pharmacological target

The depletion of CD4+ T cells in HIV infection has long been correlated with the overexpression of the cell surface adhesion receptor protein, CD38.martynowi | Shutterstock

CD38 as a predictor of CD4+ T cell depletion

CD38 overexpression is a salient aspect of chronic HIV infection and predicts the onset of AIDS with high accuracy. Its expression is consistently predictive compared to other activation markers.

Additionally, it is independent of the frequency of cycling cells. This suggests that CD38 may reflect a mechanism that is independent of the viral-mediated killing of CD4+ T cells. Alternatively, CD38 may directly contribute to T cell loss, which would require an increase in biological activity to cause CD4+ T cell loss or decreased cell renewal. This would occur alongside the HIV-mediated cell lysis and cytopathic effects (changes in host cell structure mediated by viral invasion).

Mechanism of action

The overexpression of CD38 expression during HIV infection increases it's catalytic activity. CD38 is a potent regulator of nicotinamide adenine dinucleotide (NAD), which it uses as a substrate in catalytic reactions. This produces cADPR and ADPR, which mobilize Ca2+ and subsequently increase intracellular Ca2+concentration.

The increased Ca2+concentration, together with depleted NAD, reduce the function and integrity of mitochondria. Survival and proliferation of T cells (T cell viability) from HIV infected patients is consequently reduced.

Products of CD38 catalysis

The increase in NAD turnover results in excessive production of cADPR and ADPR. cADPR activates the ryanodine receptor (RyR) calcium channel, which increases the Ca2+ transport from the endoplasmic reticulum to the cytosol. The effect is enhanced by ADBR which activates transient receptor potential melastatin 2 calcium channel (TRPM2). TRPM2 permits Ca2+ entry from outside the cell to the cytoplasm.

Interestingly, CD38 operates outside of the cell so increases the intracellular concentrations of cADPR and ADPT, which suggests CD38 acts in an autocrine and paracrine manner. The ensuing increase in cytoplasmic Ca2+ further stresses the mitochondria which mediates the release of cytochrome c and programmed cell death.

CD38 as a pharmacological target

CD38 are viable targets for therapeutic outputs. Antagonists of CD38 could be used as a therapeutic tool and act as an adjunct to existing antiretroviral therapy. The effect of this therapeutic intervention is particularly useful in gut‐associated lymphoid tissue where the antiretroviral therapy is limited.

Sources:

  • HIV Disease Progression: Overexpression of the Ectoenzyme CD38 as a Contributory Factor? 2018. Bioessays. doi/10.1002/bies.201800128
  • ADP-ribosyl Cyclase and CD38 Catalyze the Synthesis of a Calcium-mobilizing Metabolite from NADP+. 1995. The Journal of Biological Chemistry. doi:10.1074/jbc.270.51.30327.
  • Crystal Structure of Human CD38 Extracellular Domain. Cell Structure. 2005. 13;9. doi.org/10.1016/j.str.2005.05.012
  • Metabolism in T cell activation and differentiation. 2010. Current Opinion in Immunology. 22;3. doi.org/10.1016/j.coi.2010.01.018.

Further Reading

Last Updated: Apr 30, 2019

Hidaya Aliouche

Written by

Hidaya Aliouche

Hidaya is a science communications enthusiast who has recently graduated and is embarking on a career in the science and medical copywriting. She has a B.Sc. in Biochemistry from The University of Manchester. She is passionate about writing and is particularly interested in microbiology, immunology, and biochemistry.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Aliouche, Hidaya. (2019, April 30). The Role of the CD38 Receptor in the Progression of HIV. News-Medical. Retrieved on February 07, 2024 from https://www.news-medical.net/life-sciences/The-Role-of-the-CD38-Receptor-in-the-Progression-of-HIV.aspx.

  • MLA

    Aliouche, Hidaya. "The Role of the CD38 Receptor in the Progression of HIV". News-Medical. 07 February 2024. <https://www.news-medical.net/life-sciences/The-Role-of-the-CD38-Receptor-in-the-Progression-of-HIV.aspx>.

  • Chicago

    Aliouche, Hidaya. "The Role of the CD38 Receptor in the Progression of HIV". News-Medical. https://www.news-medical.net/life-sciences/The-Role-of-the-CD38-Receptor-in-the-Progression-of-HIV.aspx. (accessed February 07, 2024).

  • Harvard

    Aliouche, Hidaya. 2019. The Role of the CD38 Receptor in the Progression of HIV. News-Medical, viewed 07 February 2024, https://www.news-medical.net/life-sciences/The-Role-of-the-CD38-Receptor-in-the-Progression-of-HIV.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Amsterdam UMC project aims for first effective HIV vaccine with Gates funding